174 related articles for article (PubMed ID: 37010809)
1. Detection of BRAF V600E mutation in radiological Langerhans cell histiocytosis-associated neurodegenerative disease using droplet digital PCR analysis.
Shimizu S; Sakamoto K; Kudo K; Morimoto A; Shioda Y
Int J Hematol; 2023 Jul; 118(1):119-124. PubMed ID: 37010809
[TBL] [Abstract][Full Text] [Related]
2. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.
McClain KL; Picarsic J; Chakraborty R; Zinn D; Lin H; Abhyankar H; Scull B; Shih A; Lim KPH; Eckstein O; Lubega J; Peters TL; Olea W; Burke T; Ahmed N; Hicks MJ; Tran B; Jones J; Dauser R; Jeng M; Baiocchi R; Schiff D; Goldman S; Heym KM; Wilson H; Carcamo B; Kumar A; Rodriguez-Galindo C; Whipple NS; Campbell P; Murdoch G; Kofler J; Heales S; Malone M; Woltjer R; Quinn JF; Orchard P; Kruer MC; Jaffe R; Manz MG; Lira SA; Parsons DW; Merad M; Man TK; Allen CE
Cancer; 2018 Jun; 124(12):2607-2620. PubMed ID: 29624648
[TBL] [Abstract][Full Text] [Related]
3. ddPCR Analysis Reveals BRAF V600E Mutations Are Infrequent in Isolated Pituitary Langerhans Cell Histiocytosis Patients.
Nellan A; Bodlak A; Mirsky DM; Mulcahy Levy J; Garrington TP; Foreman NK; Gilani A; Hayashi M
J Neuropathol Exp Neurol; 2020 Dec; 79(12):1313-1319. PubMed ID: 32930721
[TBL] [Abstract][Full Text] [Related]
4. Circulating cell-free BRAF
Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
[TBL] [Abstract][Full Text] [Related]
5. Assessment of BRAF
Pierry C; Caumont C; Blanchard E; Brochet C; Dournes G; Gros A; Bandres T; Verdon S; Marty M; Bégueret H; Merlio JP
Virchows Arch; 2018 Feb; 472(2):247-258. PubMed ID: 28711990
[TBL] [Abstract][Full Text] [Related]
6. Association between clinicopathologic characteristics and BRAF
Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.
Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M
Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272
[TBL] [Abstract][Full Text] [Related]
8. High Prevalence of
Liu X; Zhang Y; Zhou CX
Int J Surg Pathol; 2019 Dec; 27(8):836-843. PubMed ID: 31203679
[TBL] [Abstract][Full Text] [Related]
9. Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis.
Kansal R; Quintanilla-Martinez L; Datta V; Lopategui J; Garshfield G; Nathwani BN
Genes Chromosomes Cancer; 2013 Jan; 52(1):99-106. PubMed ID: 22996177
[TBL] [Abstract][Full Text] [Related]
10.
Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
[TBL] [Abstract][Full Text] [Related]
11. Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry.
Méhes G; Irsai G; Bedekovics J; Beke L; Fazakas F; Rózsa T; Kiss C
Am J Surg Pathol; 2014 Dec; 38(12):1644-8. PubMed ID: 25118810
[TBL] [Abstract][Full Text] [Related]
12. [BRAF-V600E mutation and its clinical significance in children with Langerhans cell histiocytosis].
Tang X; Guo X; Sun LY; Ai Y; Yang X; Sun JJ; Wu JR; Gao J
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Apr; 20(4):290-294. PubMed ID: 29658453
[TBL] [Abstract][Full Text] [Related]
13. BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay.
Tatsuno M; Shioda Y; Iwafuchi H; Yamazaki S; Iijima K; Takahashi C; Ono H; Uchida K; Okamura O; Matubayashi M; Okuyama T; Matsumoto K; Yoshioka T; Nakazawa A
Diagn Pathol; 2016 Apr; 11():39. PubMed ID: 27094161
[TBL] [Abstract][Full Text] [Related]
14. BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases.
Roden AC; Hu X; Kip S; Parrilla Castellar ER; Rumilla KM; Vrana JA; Vassallo R; Ryu JH; Yi ES
Am J Surg Pathol; 2014 Apr; 38(4):548-51. PubMed ID: 24625419
[TBL] [Abstract][Full Text] [Related]
15. The Value of BRAF VE1 Immunoexpression in Pediatric Langerhans Cell Histiocytosis.
Phan DAT; Phung GB; Duong TT; Hoang AV; Ngo QD; Trinh DTN; Tran TT
Fetal Pediatr Pathol; 2022 Aug; 41(4):558-567. PubMed ID: 33295826
[No Abstract] [Full Text] [Related]
16. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement.
Jouenne F; Chevret S; Bugnet E; Clappier E; Lorillon G; Meignin V; Sadoux A; Cohen S; Haziot A; How-Kit A; Kannengiesser C; Lebbé C; Gossot D; Mourah S; Tazi A
Eur Respir J; 2020 Feb; 55(2):. PubMed ID: 31806714
[TBL] [Abstract][Full Text] [Related]
17. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
18. Co-existence of BRAF V600E-mutated malignant melanoma and BRAF V600E-mutated Langerhans cell histiocytosis: A case report.
Goto K; Yoshikawa S; Kiyohara Y; Kukita Y; Miura K; Oishi T
J Cutan Pathol; 2022 Apr; 49(4):393-398. PubMed ID: 34792818
[TBL] [Abstract][Full Text] [Related]
19. Frequency detection of BRAF V600E mutation in a cohort of pediatric langerhans cell histiocytosis patients by next-generation sequencing.
Feng S; Han L; Yue M; Zhong D; Cao J; Guo Y; Sun Y; Zhang H; Cao Z; Cui X; Liu R
Orphanet J Rare Dis; 2021 Jun; 16(1):272. PubMed ID: 34116682
[TBL] [Abstract][Full Text] [Related]
20. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
